Nuformix plc (LON:NFX)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.0900
+0.0090 (11.11%)
Feb 21, 2025, 5:07 PM BST
-68.42%
Market Cap 1.28M
Revenue (ttm) n/a
Net Income (ttm) -3.64M
Shares Out 1.42B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,575,366
Average Volume 126,796,063
Open 0.0775
Previous Close 0.0810
Day's Range 0.0800 - 0.1000
52-Week Range 0.0400 - 0.3000
Beta 1.14
RSI 56.57
Earnings Date Mar 19, 2025

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP0... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol NFX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.